Pfizer Inc. Chief Executive Albert Bourla had long searched for an obesity drug to make up for dwindling sales of the pharma company’s aging blockbusters. Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize.

Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration

Trump administration drug deals link U.S. prices to global lows, aiming to cut costs via Pfizer, AstraZeneca, and TrumpRx in 2026.

Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

President Trump on Tuesday announced a deal with Pfizer to sell its drugs directly to consumers at discounted prices. They'll be available through a website operated by the federal government called TrumpRx.gov. He said similar deals with other drugmakers ...

Shares of Pfizer Inc. gave up ground in early Tuesday trading, after the drug giant reported a decline in revenue, as strength in its blood-clot drug was offset by the continued drop-off in demand for COVID-19 vaccines and treatments.